Prostate cancer, Secondary cancers
Results
Phase 2
This trial looked at capivasertib and enzalutamide for men with prostate cancer that had spread and continued to grow despite having other treatment. Capivasertib is pronounced cap-i-va-ser-tib.
This trial was supported by Cancer Research UK. Men could join between 2016 and 2019. The team published the results in 2024.
Recruitment start: 6 July 2016
Recruitment end: 6 September 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
Astellas Pharma
Astra Zeneca
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research UK
The Royal Marsden NHS Foundation Trust
Last reviewed: 17 Mar 2026
CRUK internal database number: 10564
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
